What it means
The cytochrome P450 (CYP) superfamily of enzymes is responsible for the oxidative metabolism of approximately 75% of all marketed drugs. When a drug or chemical inhibits a CYP enzyme, the normal metabolism of other drugs ("substrates") processed by that enzyme is impaired. As a result, substrate drug concentrations rise in plasma — proportional to the degree of inhibition — increasing both pharmacological effects and the risk of adverse reactions.
CYP inhibition is the most common pharmacokinetic mechanism for drug–drug interactions (DDIs) ↗. Clinically relevant interactions occur when a strong inhibitor is co-administered with a narrow therapeutic index substrate — for example, ketoconazole (strong CYP3A4 inhibitor) and simvastatin (CYP3A4 substrate), increasing simvastatin exposure 10–20-fold with risk of rhabdomyolysis. The FDA CYP interaction table ↗ categorises hundreds of drugs by their CYP inhibitor/substrate status.
CYP inhibition is classified by mechanism and duration. Reversible inhibition (competitive, non-competitive, uncompetitive) resolves quickly when the inhibitor is cleared. Mechanism-based inhibition (MBI) — also called time-dependent inhibition (TDI) — involves metabolic activation of the inhibitor to a reactive species that covalently and irreversibly inactivates the CYP enzyme. MBI is clinically more dangerous because the interaction persists for days to weeks after the inhibitor is stopped, until new enzyme protein is synthesised.
Formula
| Equation | Variables | Notes |
|---|---|---|
| R = 1 + [I] / Ki | [I] = inhibitor concentration (free, at enzyme); Ki = inhibition constant | Static risk metric for reversible inhibition; R >1.25 triggers DDI study |
| AUC ratio = 1 / (1 − fm × Inh%) | fm = fraction of substrate cleared by inhibited CYP; Inh% = % enzyme inhibited | Predicted substrate AUC fold-increase |
| kdeg = kinact × [I] / (KI + [I]) | kinact = max inactivation rate; KI = inhibitor conc. at half-maximal inactivation | Rate of MBI-based enzyme destruction |
| v = Vmax × S / (Km × (1 + I/Ki) + S) | v = reaction rate; S = substrate conc.; Km = Michaelis constant | Competitive inhibition kinetics |
The FDA uses the R1 static model (R = 1 + Imax,u / Ki) and mechanistic static models for initial DDI risk screening. Dynamic physiologically based PK (PBPK) modelling is required for complex scenarios. See the FDA DDI guidance for industry ↗.
Example: clarithromycin + simvastatin
Clarithromycin ↗ is a strong mechanism-based inhibitor of CYP3A4 (via formation of a nitrosoalkane metabolite that forms a stable inhibitory complex). Co-administration with simvastatin — a CYP3A4 substrate — dramatically raises simvastatin AUC:
| Scenario | Simvastatin AUC | Fold-change | Clinical consequence |
|---|---|---|---|
| Simvastatin alone | Reference | 1× | Normal statin effect |
| + Clarithromycin (strong MBI) | ~10–20× | 10–20× | Risk of myopathy/rhabdomyolysis |
| + Erythromycin (moderate) | ~4–5× | 4–5× | Increased toxicity risk |
| Interaction duration (MBI) | Days to weeks | — | Persists after antibiotic stopped |
The simvastatin label contraindicates co-administration with strong CYP3A4 inhibitors. Alternative statins with lower CYP3A4 dependence (pravastatin, rosuvastatin) are preferred when macrolide antibiotics are required. See the simvastatin DailyMed label ↗ and enzyme inhibition overview.
Common mix-ups
Inhibition raises substrate drug levels (immediate effect, resolved when inhibitor cleared). Induction lowers substrate levels (delayed effect over 1–2 weeks, requires gene transcription). Both are DDI mechanisms but in opposite directions.
Reversible inhibition resolves within hours to days after the inhibitor is stopped (tied to inhibitor half-life). Mechanism-based inhibition (MBI) persists for days to weeks regardless — the enzyme is permanently destroyed. Stopping clarithromycin does not immediately restore CYP3A4 activity.
The magnitude of the DDI depends on the fraction of substrate cleared by CYP3A4 (fm). Substrates with high fm (>0.9) show large AUC increases with strong inhibitors. Those with low fm (<0.3) — because other pathways dominate — show modest increases. Fm values are published in drug labels and the FDA interaction table ↗.
Grapefruit juice inhibits intestinal CYP3A4 only (not hepatic), selectively increasing oral bioavailability of high-extraction drugs without affecting IV pharmacokinetics. Systemic inhibitors (ketoconazole, ritonavir) inhibit both intestinal and hepatic CYP3A4, affecting all routes. This distinction matters for first-pass metabolism predictions.
FAQ
What is CYP enzyme inhibition?
CYP enzyme inhibition is the blockade of cytochrome P450 (CYP) enzymes ↗ by an inhibitor drug, slowing metabolism of substrate drugs and raising their plasma concentrations — increasing pharmacological effects and toxicity risk. It is the most common mechanism of clinically significant pharmacokinetic drug-drug interactions (DDIs) ↗.
What is the difference between reversible and mechanism-based CYP inhibition?
Reversible inhibition (competitive, non-competitive) resolves when the inhibitor is eliminated. Mechanism-based inhibition (MBI), also called time-dependent inhibition (TDI), involves metabolic activation to a reactive species that covalently inactivates the enzyme — the effect persists until new enzyme is synthesised (days to weeks). Clinically important MBI inhibitors include grapefruit juice ↗, clarithromycin, erythromycin, and mibefradil.
Which CYP enzymes are most clinically important for drug interactions?
CYP3A4: most abundant, metabolises ~50% of all drugs — major inhibitors include ketoconazole, ritonavir, clarithromycin. CYP2D6: ~25% of drugs (antidepressants, antipsychotics, opioids). CYP2C9: warfarin, NSAIDs, sulfonylureas. CYP2C19: clopidogrel (activation), PPIs. CYP1A2: theophylline, clozapine. The FDA CYP interaction table ↗ lists substrates, inhibitors, and inducers.
How does CYP inhibition affect drug plasma levels?
CYP inhibition decreases substrate clearance, increases AUC, and raises plasma levels. For narrow therapeutic index drugs (warfarin, cyclosporine, digoxin), modest inhibition can cause toxicity. The magnitude is quantified by the R-value: R = 1 + [I] / Ki, where [I] is inhibitor concentration at the enzyme and Ki is the inhibition constant. See the FDA DDI guidance ↗.
What is competitive CYP inhibition?
Competitive inhibition occurs when the inhibitor binds reversibly to the CYP active site, competing with the substrate. It increases apparent Km but does not change Vmax. The effect is immediately reversible and concentration-dependent. Classical examples: fluconazole (CYP2C9) ↗, ketoconazole (CYP3A4). Competitive inhibition of warfarin metabolism by fluconazole requires warfarin dose reduction of 50% or more.
Which drugs are strong CYP3A4 inhibitors?
Strong CYP3A4 inhibitors (>5-fold AUC increase): ketoconazole, itraconazole, clarithromycin, ritonavir, cobicistat, grapefruit juice (intestinal). Moderate (2–5-fold): erythromycin, verapamil, diltiazem, fluconazole. Weak (<2-fold): amiodarone, cimetidine. This classification follows the FDA DDI guidance ↗ and the EMA DDI guideline ↗.
How is CYP inhibition assessed during drug development?
In vitro studies (human liver microsomes, recombinant CYPs) measure IC50 and Ki for reversible inhibition, and kinact/KI for MBI. The FDA DDI guidance ↗ and EMA DDI guideline ↗ require in vitro CYP inhibition screening for all new molecular entities. If the R-value predicts >1.25-fold AUC change for a sensitive substrate, a clinical DDI study is mandated.